Pediatric Outpatient Fluoroquinolone Dispensing After EMA/AIFA Safety Restrictions: A Regional Interrupted Time-Series Analysis from Southern Italy

Background/Objectives: Pediatric fluoroquinolone use is restricted because of safety concerns and antimicrobial-stewardship priorities. We described outpatient dispensing trends in Apulia, Italy, during 2019–2024 and examined whether the June 2023 EMA/AIFA safety reminder coincided with an additional change in utilization. Methods: This regional population-based drug-utilization study analysed reimbursed outpatient fluoroquinolone dispensing records among residents aged 0–14 years. Annual rates were expressed per 1000 pediatric residents; defined daily doses (DDDs) were secondary measures. Monthly dispensing-record rates were analysed by segmented interrupted time-series regression, using June 2023 as the interruption and Newey–West standard errors (maximum lag 3). Results: Dispensing records fell from 786 in 2019 to 509 in 2024 (−35.2%), and standardized rates decreased from 1.51 to 1.08 per 1000 pediatric residents (−28.2%). DDD per 1000 residents decreased from 8.30 to 5.65. The estimated pre-reminder monthly slope was negative but not statistically significant (β = −0.000522; p = 0.305). Neither the immediate level change (β = +0.013316; p = 0.415) nor the post-reminder slope change (β = −0.000150; p = 0.852) was statistically significant. Results for all fluoroquinolones were robust to sensitivity analyses addressing seasonality and the COVID-19 pandemic; for ciprofloxacin, two exploratory specifications yielded nominally significant level increases. Conclusions: Pediatric outpatient fluoroquinolone dispensing in Apulia decreased over six years, although its trajectory was not monotonic. The interrupted time-series analysis detected no statistically significant additional level or slope change following the June 2023 reminder. These findings describe utilization within an evolving regulatory and stewardship context but cannot establish the effects of earlier restrictions or assess the clinical appropriateness of individual dispensings.

Authors

Institutions

Publication Details

Journal
Antibiotics
Published
2026-11-18
DOI
https://doi.org/10.3390/antibiotics15111151
Primary Topic
Antibiotic Use and Resistance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pediatric Outpatient Fluoroquinolone Dispensing After EMA/AIFA Safety Restrictions: A Regional Interrupted Time-Series Analysis from Southern Italy

Cataldo Procacci, Pasquale Stefanizzi, Silvio Tafuri, Maurizio Aricò et al.
Antibiotics
Antibiotic Use and Resistance
article

Pediatric Outpatient Fluoroquinolone Dispensing After EMA/AIFA Safety Restrictions: A Regional Interrupted Time-Series Analysis from Southern Italy

Cataldo Procacci, Pasquale Stefanizzi, Silvio Tafuri, Maurizio Aricò, Claudia Palmieri
article en

Abstract

Background/Objectives: Pediatric fluoroquinolone use is restricted because of safety concerns and antimicrobial-stewardship priorities. We described outpatient dispensing trends in Apulia, Italy, during 2019–2024 and examined whether the June 2023 EMA/AIFA safety reminder coincided with an additional change in utilization. Methods: This regional population-based drug-utilization study analysed reimbursed outpatient fluoroquinolone dispensing records among residents aged 0–14 years. Annual rates were expressed per 1000 pediatric residents; defined daily doses (DDDs) were secondary measures. Monthly dispensing-record rates were analysed by segmented interrupted time-series regression, using June 2023 as the interruption and Newey–West standard errors (maximum lag 3). Results: Dispensing records fell from 786 in 2019 to 509 in 2024 (−35.2%), and standardized rates decreased from 1.51 to 1.08 per 1000 pediatric residents (−28.2%). DDD per 1000 residents decreased from 8.30 to 5.65. The estimated pre-reminder monthly slope was negative but not statistically significant (β = −0.000522; p = 0.305). Neither the immediate level change (β = +0.013316; p = 0.415) nor the post-reminder slope change (β = −0.000150; p = 0.852) was statistically significant. Results for all fluoroquinolones were robust to sensitivity analyses addressing seasonality and the COVID-19 pandemic; for ciprofloxacin, two exploratory specifications yielded nominally significant level increases. Conclusions: Pediatric outpatient fluoroquinolone dispensing in Apulia decreased over six years, although its trajectory was not monotonic. The interrupted time-series analysis detected no statistically significant additional level or slope change following the June 2023 reminder. These findings describe utilization within an evolving regulatory and stewardship context but cannot establish the effects of earlier restrictions or assess the clinical appropriateness of individual dispensings.

AntibioticsVol. 15(11)
University of Bari Aldo Moro (IT)
Good health and well-being
Antibiotic Use and Resistance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon